PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...
Treace Medical Concepts (NASDAQ:TMCI) management told investors it is entering what it called a “transformational phase,” ...
Treace Medical Concepts, Inc. announced that it will release its financial results for the fourth quarter and full year of 2024 on February 27, 2025, after market close. A conference call with company ...
PONTE VEDRA, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...
PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts (TMCI), Inc. , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related ...
PONTE VEDRA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related ...
Successful completion of first cases utilizing the SpeedPlate™ MicroQuad™ implants, indicating progress in product development. The MicroQuad™ implant enhances the existing SpeedPlate™ platform, which ...
NEW YORK, May 16, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace" or the "Company") ...
TMCI investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...
) has been revised to $5.58 / share. This is a decrease of 35.65% from the prior estimate of $8.67 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
CEO Treace stated, "we are not growing our line the way we anticipated for the year," while also noting case volume growth in Q3 2025 was still below original expectations and driven by lower-ASP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results